In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Shire options Cortex 's Ampalex for ADHD; terminated

Executive Summary

In an agreement with an option for an exclusive worldwide license, Shire Pharmaceuticals will evaluate Cortex Pharmaceuticals' Ampalex (CX516) for attention deficit hyperactivity disorder. Shire will invest (uf)$1mm up front ($870k in Cortex stock and $130k in cash) and fund all clinical trials.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies